GINECO (Groupe d`Investigation National pour l`Etude des Cancers de l`Ovaire et du être) is the French cooperative oncology group, awarded by the INCA (National Cancer Institute in France), which develops and carries out clinical studies on gynecological and metastatic breast cancer at the national and international levels. The network brings together more than 700 specialized researchers representing more than 150 public or private oncology units. In preclinical studies, NP137 inhibited tumor growth and had a significant effect on tumor plasticity, which enhances the effectiveness of chemotherapy and immune checkpoint inhibitors. In the “Phase 1 dose escalation study, NP137 s” was found to be safe and very well tolerated up to 20 mg/kg, with no dose limit toxicity (DLT). In addition, patients with advanced uterine cancer showed encouraging signs of antitotum activity, including persistent stable disease and objective reactions. . . .